[1]
Upadhyay, R. Diabetic hepatopathy. In:API Text Book of Medicine; Munjal, Y.P., Ed.; , 2017, p. 314.
[2]
Rubio-Rivas, M.; Montero-Alía, P.; Ordi-Ros, J.; Labrador, M. Hepatic glycogenosis and diabetes mellitus. Med. Clin. (Barc.), 2005, 125, 279.
[3]
Nazzari, E.; Grillo, F.; Celiento, T.; Picciotto, A.; Ferone, D.; Murialdo, G.; Ameri, P. Diabetic hepatosclerosis presenting with severe cholestasis. Diabetes Care, 2013, 36(12), e206.
[4]
Levinthal, G.N.; Tavill, A.S. Liver disease and diabetes mellitus. Clin. Diabetes, 1999, 1, 431-443.
[5]
Nishida, T.; Tsuji, S.; Tsujii, M.; Arimitsu, S.; Haruna, Y.; Imano, E.; Suzuki, M.; Kanda, T.; Kawano, S.; Hiramatsu, N.; Hayashi, N.; Hori, M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am. J. Gastroenterol., 2006, 101, 70-75.
[6]
Kim, M.G.; Choi, W.C. Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other Type 2 diabetes mellitus. Korean J. Hepatol., 2006, 12, 524-529.
[7]
Zhang, X.; Shen, W.; Shen, D.M. A clinical analysis of liver disease patients with abnormal glucose metabolism. Zhonghua Gan Zang Bing Za Zhi, 2006, 14, 289-292.
[8]
Hamed, A.E.; Abas, B.; Shaltout, I.; Esmt, G.; Gomez, R.; Kumar, A.; Assad, S.H.; Elsahar, M.; Elweakil, R.; Salih, S.; Elkhatib, A.; Hamed, H.; Elwan, N.; AbdelMaqsod, A.; Sakr, M.A.; Emil, S.; Mogawer, S.; Magdeldin, H.; Zakaria, A.; Elgarem, H.; Soltan, S.; Salih, O.; Shawki, M.; Kamel, M.; Hamza, I. Managing diabetes and liver disease association guidelines (consensus) development. J. Endocrinol. Diabetes Obes., 2015, 3(3), 1073.
[9]
Petäjä, E.M.; Yki-Järvinen, H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-A systematic review. Int. J. Mol. Sci., 2016, 17(5), pii: E633.
[10]
Abdeldyem, S.M.; Goda, T.; Khodeir, S.A.; AbouSaif, S.; Abd-Elsalam, S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J. Clin. Lipidol., 2017, 11(4), 915-919.
[11]
Ahmed, M. Non-alcoholic fatty liver disease in 2015. World J. Hepatol., 2015, 7(11), 1450-1459.
[12]
Prashanth, M.; Ganesh, H.K.; Vima, M.V.; John, M.; Bandgar, T.; Joshi, S.R.; Shah, S.R.; Rathi, P.M.; Joshi, A.S.; Thakkar, H.; Menon, P.S.; Shah, N.S. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J. Assoc. Physicians India, 2009, 57, 205-210.
[13]
Leite, N.C.; Salles, G.F.; Araujo, A.L.; Villela-Nogueira, C.A.; Cardoso, C.R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int., 2009, 29, 113-119.
[14]
Chan, W.K.; Tan, A.T.; Vethakkan, S.R.; Tah, P.C.; Vijayananthan, A.; Goh, K.L. Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J. Gastroenterol. Hepatol., 2013, 28(8), 1375-1383.
[15]
Stepanova, M.; Rafiq, N.; Younossi, Z.M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut, 2010, 59, 1410-1415.
[16]
Hazlehurst, J.M.; Woods, C.; Marjot, T.; Cobbold, J.F.; Tomlinson, J.W. Non-alcoholic fatty liver disease and diabetes. Metabolism, 2016, 65(8), 1096-1108.
[17]
Ming, J.; Xu, S.; Gao, B.; Liu, G.; Ji, Y.; Yang, F.; Jia, Y.; Fang, Y.; Ji, Q. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: A five-year cohort study. Liver Int., 2015, 35, 2401-2407.
[18]
Li, W.D.; Fu, K.F.; Li, G.M.; Lian, Y.S.; Ren, A.M.; Chen, Y.J.; Xia, J.R. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J. Gastroenterol., 2015, 21, 9607-9613.
[19]
Fukuda, T.; Hamaguchi, M.; Kojima, T.; Hashimoto, Y.; Ohbora, A.; Kato, T.; Nakamura, N.; Fukui, M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int., 2016, 36, 275-283.
[20]
Shibata, M.; Kihara, Y.; Taguchi, M.; Tashiro, M.; Otsuki, M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care, 2007, 30, 2940-2944.
[21]
Bae, J.C.; Rhee, E.J.; Lee, W.Y.; Park, S.E.; Park, C.Y.; Oh, K.W.; Park, S.W.; Kim, S.W. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care, 2011, 34, 727-729.
[22]
Li, X.; Stevens, P.D.; Liu, J.; Yang, H.; Wang, W.; Wang, C.; Zeng, Z.; Schmidt, M.D.; Yang, M.; Lee, E.Y.; Gao, T. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology, 2014, 146, 1301-1312.
[23]
Ghalali, A.; Ye, Z.W.; Hogberg, J.; Stenius, U. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor beta-activated stem cells. J. Biol. Chem., 2014, 289, 11601-11615.
[24]
Ballestri, S.; Zona, S.; Targher, G.; Romagnoli, D.; Baldelli, E.; Nascimbeni, F.; Roverato, A.; Guaraldi, G.; Lonardo, A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol., 2016, 31, 936-944.
[25]
Bae, J.C.; Cho, Y.K.; Lee, W.Y.; Seo, H.I.; Rhee, E.J.; Park, S.E.; Park, C.Y.; Oh, K.W.; Sung, K.C.; Kim, B.I. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am. J. Gastroenterol., 2010, 11, 2389-2395.
[26]
Pardina, E.; Baena-Fustegueras, J.A.; Catalán, R.; Galard, R.; Lecube, A.; Fort, J.M.; Allende, H.; Vargas, V.; Peinado-Onsurbe, J. Increased expression and activity of hepatic lipase in the liver of morbidly obese adult patients in relation to lipid content. Obes. Surg., 2009, 19(7), 894-904.
[27]
Mittendorfer, B.; Magkos, F.; Fabbrini, E.; Mohammed, B.S.; Klein, S. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring), 2009, 17(10), 1872-1877.
[28]
Adams, L.A.; Sanderson, S.; Lindor, K.D.; Angulo, P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol., 2005, 42, 132-138.
[29]
Valenti, L.; Bugianesi, E.; Pajvani, U.; Targher, G. Nonalcoholic fatty liver disease: Cause or consequence of type 2 diabetes? Liver Int., 2016, 36(11), 1563-1579.
[30]
Targher, G.; Day, C.P.; Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med., 2010, 363, 1341-1350.
[31]
McPherson, S.; Hardy, T.; Henderson, E.; Burt, A.D.; Day, C.P.; Anstee, Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol., 2015, 62(5), 1148-1155.
[32]
Raff, E.J.; Kakati, D.; Bloomer, J.R.; Shoreibah, M.; Rasheed, K.; Singal, A.K. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J. Clin. Transl. Hepatol., 2015, 3(1), 9-16.
[33]
Lomonaco, R.; Bril, F.; Portillo-Sanchez, P.; Ortiz-Lopez, C.; Orsak, B.; Biernacki, D.; Lo, M.; Suman, A.; Weber, M.H.; Cusi, K. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care, 2016, 39(4), 632-638.
[34]
Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Tessari, R.; Zenari, L.; Day, C.; Arcaro, G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007, 30(5), 1212-1218.
[35]
Mantovani, A.; Pernigo, M.; Bergamini, C.; Bonapace, S.; Lipari, P.; Pichiri, I.; Bertolini, L.; Valbusa, F.; Barbieri, E.; Zoppini, G.; Bonora, E.; Targher, G. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One, 2015, 10(8), e0135329.
[36]
Jia, G.; Di, F.; Wang, Q.; Shao, J.; Gao, L.; Wang, L.; Li, Q.; Li, N. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS One, 2015, 10(11), e0142808.
[37]
Yamazaki, H.; Tsuboya, T.; Tsuji, K.; Dohke, M.; Maguchi, H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of Type 2 diabetes. Diabetes Care, 2015, 38, 1673-1679.
[38]
Sherigar, J.M.; De Castro, J.; Yin, Y.M.; Guss, D.; Mohanty, S.R. Glycogenic hepatopathy: A narrative review. World J. Hepatol., 2018, 10(2), 172-185.
[39]
Gutch, M.; Philip, R.; Saran, S.; Tyagi, R.; Gupta, K.K. Re-emergence of a rare syndrome: A case of mauriac syndrome. Indian J. Endocrinol. Metab., 2013, 17, 283-285.
[40]
Silva, M.; Marques, M.; Cardoso, H.; Rodrigues, S.; Andrade, P.; Peixoto, A.; Pardal, J.; Lopes, J.; Carneiro, F.; Macedo, G. Glycogenic hepatopathy in young adults: a case series. Rev. Esp. Enferm. Dig., 2016, 108(10), 673-676.
[41]
Van den Brand, M.; Elving, L.D.; Drenth, J.P.; van Krieken, J.H. Glycogenic hepatopathy: a rare cause of elevated serum transaminases in diabetes mellitus. Neth. J. Med., 2009, 67(11), 394-396.
[42]
El-Karaksy, H.M.; Anwar, G.; Esmat, G.; Mansour, S.; Sabry, M.; Helmy, H.; El-Hennawy, A.; Fouad, H. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr. Diabetes, 2010, 11, 462-470.
[43]
Imtiaz, K.; Healy, C.; Sharif, S.; Drake, I.; Awan, F.; Riley, J.; Karlson, F. Glycogenic hepatopathy in type 1 diabetes: an under recognized condition. Diabetes Care, 2013, 36(1), e6-e7.
[44]
Umpaichitra, V. Unusual glycogenic hepatopathy causing abnormal liver enzymes in a morbidly obese adolescent with well-controlled type 2 diabetes: resolved after A1c was normalized by metformin. Clin. Obes., 2016, 6(4), 281-284.
[45]
Resnick, J.M.; Zador, I.; Fish, D.L. Dumping syndrome, a cause of acquired glycogenic hepatopathy. Pediatr. Dev. Pathol., 2011, 14, 318-321.
[46]
Parmara, N.; Atiqb, M.; Austinb, L.; Miller, R.A.; Smyrk, T.; Ahmed, K. Glycogenic hepatopathy: Thinking outside the box. Case Rep. Gastroenterol., 2015, 9, 221-226.
[47]
Torbenson, M.; Chen, Y.Y.; Brunt, E.; Cummings, O.W.; Gottfried, M.; Jakate, S.; Liu, Y.C.; Yeh, M.M.; Ferrell, L. Glycogenic hepatopathy: An under recognized hepatic complication of diabetes mellitus. Am. J. Surg. Pathol., 2006, 30, 508-513.
[48]
Masuoka, H.C.; Chalasani, N. Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals. Ann. N. Y. Acad. Sci., 2013, 1281, 106-122.
[49]
Morton, A. Is it possible to distinguish between glycogenic hepatopathy and non-alcoholic fatty liver disease without liver biopsy? Intern. Med. J., 2016, 46(10), 1232.
[50]
Al-Hussaini, A.; Sulaiman, N.; AlZahrani, M.; Alenizi, A.S.; Khan, M. Prevalence of hepatopathy in type 1 diabetic as a cause of recurrent liver damage. BMC Pediatr., 2012, 12, 160.
[51]
Ikarashi, Y.; Kogiso, T.; Hashimoto, E.; Yamamoto, K.; Kodama, K.; Taniai, M.; Torii, N.; Takaike, H.; Uchigata, Y.; Tokushige, K. Four cases of type 1 diabetes mellitus showing sharp serum transaminase increases and hepatomegaly due to glycogenic hepatopathy. Hepatol. Res., 2017, 47(3), E201-E209.
[52]
Deemer, K.S.; Alvarez, G.F. A rare case of persistent lactic acidosis in the ICU: Glycogenic hepatopathy and mauriac syndrome. Hindawi Publishing Corporation. 2016, Article ID 6072909, pp.1-4.
[53]
King, R.J.; Harrison, L.; Gilbey, S.G.; Santhakumar, A.; Wyatt, J.; Jones, R.; Bodansky, H.J. Diabetic hepatosclerosis: another diabetes microvascular complication? Diabet. Med., 2016, 33, 5-7.
[54]
Hudacko, R.M.; Sciancalepore, J.P.; Fyfe, B.S. Diabetic microangiopathy in the liver: an autopsy study of incidence and association with other diabetic complications. Am. J. Clin. Pathol., 2009, 132, 494-499.
[55]
Harrison, S.A.; Brunt, E.M.; Goodman, Z.D.; Di Bisceglie, A.M. Diabetic hepatosclerosis: Diabetic microangiopathy of the liver. Arch. Pathol. Lab. Med., 2006, 130(1), 27-32.
[56]
Garcia-Compean, D.; Jaquez-Quintana, J.O.; Gonzalez-Gonzalez, J.A.; Maldonado-Garza, H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol., 2009, 15(3), 280-288.
[57]
Orsi, E.; Grancini, V.; Menini, S.; Aghemo, A.; Pugliese, G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int., 2017, 37, 950-962.
[58]
García-Compeán, D.; González-González, J.A.; Lavalle-González, F.J.; González-Moreno, E.I.; Villarreal-Pérez, J.Z.; Maldonado-Garza, H.J. Hepatogenous diabetes: is it a neglected condition in chronic liver disease? World J. Gastroenterol., 2016, 22, 2869-2874.
[59]
El-Zayadi, A.R.; Selim, O.E.; Hamdy, H.; Dabbous, H.; Ahdy, A.; Moniem, S.A. Association of chronic hepatitis C infection and diabetes mellitus. Trop. Gastroenterol., 1998, 19, 141-144.
[60]
Kawaguchi, T.; Taniguchi, E.; Itou, M.; Sakata, M.; Sumie, S.; Sata, M. Insulin resistance and chronic liver disease. World J. Hepatol., 2011, 3, 99-107.
[61]
American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018. Diabetes Care, 2018, 41(1), 13-27.
[62]
Cacciatore, L.; Cozzolino, G.; Giardina, M.G.; De Marco, F.; Sacca, L.; Esposito, P.; Schnedl, W.J. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res., 1988, 7, 185-188.
[63]
García-Compeán, D.; Jáquez-Quintana, J.O.; Lavalle-González, F.J.; Reyes-Cabello, E.; González-González, J.A.; Muñoz-Espinosa, L.E.; Vázquez-Elizondo, G.; Villarreal-Pérez, J.Z.; Maldonado-Garza, H.J. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann. Hepatol., 2012, 11, 240-248.
[64]
Zhang, L.; Shi, Y.L.; Hong, W.X.; Jia, W.D.; Li, L.H. Diagnostic value of serum islet autoantibody in hepatogenic diabetes mellitus. Nan Fang Yi Ke Da Xue Xue Bao, 2006, 26(7), 1034-1036.
[65]
Krishnan, S.M.; Dixit, N.M. Estimation of red blood cell lifespan from alveolar carbon monoxide measurements. Transl. Res., 2009, 154, 15-17.
[66]
Mittman, N.; Desiraju, B.; Fazil, I.; Kapupara, H.; Chattopadhyay, J.; Jani, C.M.; Avram, M.M. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int., 2010, 117, 41-45.
[67]
Koga, M.; Kasayama, S. Clinical impact of glycated albumin as another glycemic control marker. Endocr. J., 2010, 57(9), 751-762.
[68]
Clar, C.; Barnard Katharine, D.; Cummins, E.; Royle, P.; Waugh, N. Aberdeen Health Technology Assessment Group. Self-monitoring of blood glucose in type 2 diabetes: Systematic review. Health Technol. Assess., 2010, 14(12), 1-140.
[69]
Poolsup, N.; Suksomboon, N.; Kyaw, A.M. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol. Metab. Syndr., 2013, 5, 39.
[70]
Blendea, M.C.; Thompson, M.J.; Malkani, S. Diabetes and chronic liver disease: etiology and pitfalls in monitoring. Clin. Diabetes, 2010, 28(4), 139-144.
[71]
Younossi, Z.M.; Loomba, R.; Rinella, M.E.; Bugianesi, E.; Marchesini, G.; Neuschwander-Tetri, B.A.; Serfaty, L.; Negro, F.; Caldwell, S.H.; Ratziu, V.; Corey, K.E.; Friedman, S.L.; Abdelmalek, M.F.; Harrison, S.A.; Sanyal, A.J.; Lavine, J.E.; Mathurin, P.; Charlton, M.R.; Chalasani, N.P.; Anstee, Q.M.; Kowdley, K.V.; George, J.; Goodman, Z.D.; Lindor, K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2018, 68(1), 361-371.
[72]
Wasfy, E.; Elkassas, G.; Elnawasany, S.; Elkasrawy, K.; Abd-Elsalam, S.; Soliman, S.; Badawi, R. Predicting esophageal varices in cirrhotic hepatitis C virus patients using noninvasive measurement of insulin resistance variables. Endocr. Metab. Immune Disord. Drug Targets, 2018, 18(6), 573-580.
[73]
Abdelmoemen, G.; Khodeir, S.A.; Zaki, A.N.; Kassab, M.; Abou-Saif, S.; Abd-Elsalam, S. Overexpression of hepassocin in diabetic patients with nonalcoholic fatty liver disease may facilitate increased hepatic lipid accumulation. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(2), 185-188.